Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tiziana Life Sciences PLC

1.12
-0.0200-1.75%
Post-market: 1.120.00000.00%16:05 EDT
Volume:107.85K
Turnover:121.81K
Market Cap:122.18M
PE:-8.39
High:1.18
Open:1.14
Low:1.10
Close:1.14
Loading ...

Tiziana Life Sciences Shares Higher on Positive Results for Spinal Cord Injury Treatment

Dow Jones
·
24 Jan

Tiziana Life Sciences' Foralumab Demonstrates Motor Function Improvement in Preclinical Spinal Cord Injury Studies

MT Newswires Live
·
24 Jan

Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-Cd3

THOMSON REUTERS
·
24 Jan

Tiziana Life Sciences Says it Has No Immediate Capital Raising Plans; Shares Fall

MT Newswires Live
·
23 Jan

Tiziana Life Sciences Not to Engage in Capital Raising Activities for the Immediate Future

THOMSON REUTERS
·
23 Jan

Tiziana Life Sciences not to engage in capital raising activities for the immediate future

GlobeNewswire
·
23 Jan

BRIEF-Tiziana Announces Discovery Of New Immune Biomarkers In Multiple Sclerosis Patients Treated With Nasal Foralumab

Reuters
·
23 Jan

Tiziana Life Sciences announces discovery of new immune biomarkers

TIPRANKS
·
23 Jan

Tiziana Life Sciences Ltd - Gene Expression Changes Detected Three Months After Foralumab Dosing

THOMSON REUTERS
·
23 Jan

Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated With Nasal Foralumab

THOMSON REUTERS
·
23 Jan

3 Penny Stocks In US With Market Caps Below $300M

Simply Wall St.
·
13 Jan

BRIEF-Tiziana Announces Reduction Of Side Effects Commonly Seen With Discontinuation Of GLP-1 Agonists With Nasal Anti-CD3

Reuters
·
10 Jan

Tiziana Life Sciences announces findings on nasal anti-CD3 monoclonal antibody

TIPRANKS
·
10 Jan

Tiziana Life Sciences: Reduction of Side Effects Seen With Discontinuation of Glp-1 Agonists With Nasal Anti-Cd3

THOMSON REUTERS
·
10 Jan

Tiziana Life Sciences Ltd - FDA Allows Additional 20 Patients in Foralumab Expanded Access Program

THOMSON REUTERS
·
10 Jan

Tiziana Life Sciences Ltd - Glp-1 Drugs Face Long Term Tolerability Issues

THOMSON REUTERS
·
10 Jan